SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation I1171N

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas

The purpose of this study is to determine the response and the duration of it in patients affected by ALK+ lymphoma that are resistant or refractory to standard cytotoxic treatment that will be treated with crizotinib.

NCT02419287 Anaplastic Large Cell Lymphoma, ALK-Positive Drug: crizotinib
MeSH:Lymphoma Lymphoma, Large-Cell, Anaplastic
HPO:Anaplastic large-cell lymphoma Lymphoma

Although crizotinib shows activity, relapses occur typically within 5 months after starting treatment and were supported by mutations like I1171N. --- I1171N ---

Primary Outcomes

Measure: objective response rates (ORR) in subjects with ALK+ lymphomas resistant or refractory to standard cytotoxic treatment, according to RECIST 1.1 criteria.

Time: the entire duration of the study (5 years)

Measure: Duration ORR

Time: the entire duration of the study (5 years)

Secondary Outcomes

Measure: Progression free survival (PFS) in ALK+ lymphoma patients treated with crizotinib, that are resistant or refractory to standard cytotoxic treatment.

Time: the entire duration of the study (5 years)

Measure: Number of patients with adverse events after crizotinib treatment

Time: the entire duration of the study (5 years)

Measure: Quality of Life (QoL) in this population of patients using the the EORTC - C30 Quality of Life questionnaire

Time: the entire duration of the study (5 years)

Measure: Overall survival (OS) in ALK+ lymphoma patients treated with crizotinib

Time: the entire duration of the study (5 years)


HPO Nodes